|Day Low/High||59.73 / 60.54|
|52 Wk Low/High||41.92 / 69.26|
Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results for TECENTRIQ from the Phase III study, OAK.
Rogers Corporation (NYSE:ROG) will be participating in the Drexel Hamilton Telecom, Media & Technology Conference on Wednesday, September 7, 2016 in New York, NY.
The stock gaped to the downside Tuesday and has continued lower today.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ACM, ACTS, BID, CC, COH, COKE, DSCI, EGRX, FNV, NWS, SHO, SSNC Downgrades: AMBC, HHC, HLF, LXFR, ROG, TCP Initiations: APLE, CNXR, EKSO, GNL, HLTH, LIND Read on to get TheStreet Quant Ratings' detailed report:
Rogers Corporation (NYSE:ROG), a global leader in engineered materials solutions, announced today it will relocate its global headquarters from Rogers, Connecticut to Chandler, Arizona.
Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 second quarter.
Automated workflows and integrated IT solutions that connect chemistry, coagulation and molecular diagnostics promise to deliver results to physicians faster, more reliably
HEAT-Seq Target Enrichment Systems help provide fast, accurate detection of human genetic variants
Rogers Corporation (NYSE: ROG) plans to announce results for its 2016 second quarter after the close of trading on Monday, August 8, 2016.
The first CLIA-waived, real-time PCR test that differentiates flu and RSV in 20 minutes is available now for use in physician offices and urgent care settings
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III GOYA study evaluating Gazyva ® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated...
Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection medium commonly used for Pap tests
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.
Rogers Corporation (NYSE:ROG) will be participating in the Sixteenth Annual CJS Securities "New Ideas" Summer Conference on Tuesday, July 12, 2016 in White Plains, NY.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.
The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.
First IVD company to provide a fully integrated solution for PCT testing with Elecsys BRAHMS PCT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra ® (tocilizumab) in people with giant cell...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28)...
Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy